View in EDS HTML Full Text PDF Full Text

TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study.

Saved in:
Bibliographic Details
Title: TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study.
Authors: Li Y; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Yuan H; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Yao QJ; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Geng X; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Xu F; Department of Minimal-Invasive Intervention, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China., Fan W; Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China., Wu G; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Cao GS; Department of Intervention, Henan Provincial People's Hospital, Zhengzhou, China., Song HY; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Hu HT; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Source: Frontiers in oncology [Front Oncol] 2025 Oct 16; Vol. 15, pp. 1652319. Date of Electronic Publication: 2025 Oct 16 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41179689
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Yuan+H%22">Yuan H</searchLink>; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Yao+QJ%22">Yao QJ</searchLink>; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Geng+X%22">Geng X</searchLink>; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Xu+F%22">Xu F</searchLink>; Department of Minimal-Invasive Intervention, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Fan+W%22">Fan W</searchLink>; Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wu+G%22">Wu G</searchLink>; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Cao+GS%22">Cao GS</searchLink>; Department of Intervention, Henan Provincial People's Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Song+HY%22">Song HY</searchLink>; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Hu+HT%22">Hu HT</searchLink>; Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Oct 16; Vol. 15, pp. 1652319. <i>Date of Electronic Publication: </i>2025 Oct 16 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41179689
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2025.1652319
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1652319
    Titles:
      – TitleFull: TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Yuan H
      – PersonEntity:
          Name:
            NameFull: Yao QJ
      – PersonEntity:
          Name:
            NameFull: Geng X
      – PersonEntity:
          Name:
            NameFull: Xu F
      – PersonEntity:
          Name:
            NameFull: Fan W
      – PersonEntity:
          Name:
            NameFull: Wu G
      – PersonEntity:
          Name:
            NameFull: Cao GS
      – PersonEntity:
          Name:
            NameFull: Song HY
      – PersonEntity:
          Name:
            NameFull: Hu HT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 10
              Text: 2025 Oct 16
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1